IDEXX Laboratories Inc. has announced the launch of the Catalyst® Cortisol Test, designed to measure real-time quantitative cortisol concentrations in dogs. This test aids in diagnosing Addison's disease and managing Cushing's syndrome, marking the third expansion of the Catalyst platform within a year. The Catalyst Cortisol Test is integrated with IDEXX Vetlab® Station and VetConnect® PLUS, providing real-time interpretive guidance during patient visits. The new test offers a load-and-go workflow, allowing it to run alone or with additional chemistry tests from a single sample. This feature is intended to improve efficiency by reducing sample preparation time and ensuring consistent results. The Catalyst Cortisol Test will be available in the U.S. and Canada by the end of July 2025, with an international rollout planned for the third quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。